Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Breast 1

Conditions

Polycystic Ovary Syndrome 13Obesity 6Weight Loss 5Overweight 3Menstruation Disturbances 2Intermittent Fasting 2Insulin Resistance 2Tumor Surgery 1Sarcopenia 1Postoperative Complications 1Obesity, Abdominal 1Muscle Weakness 1Motor Activity 1Moderately Overweight Individuals 1Metabolic Syndrome 1Metabolic Diseases 1Infertility 1Glucocorticoid Receptor Deficiency 1Fasting 1Esophageal Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1Breast Cancer Female 1Body Weight 1

Interventions

Trastuzumab 594Paclitaxel 561Cyclophosphamide 545Docetaxel 478Capecitabine 387Letrozole 350Fulvestrant 310Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 175Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × Caloric Restriction × Clear all
NCT02940470 2018-08-03

Weight Loss Pilot Study in Postmenopausal Breast Cancer Survivors

USDA Grand Forks Human Nutrition Research Center

Phase NA Completed
22 enrolled
BreastOther

Breast Neoplasms, Obesity, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon âš¡